

ORPHIT

One line pitch:

ORPHIT develops YMALZEN to treat Alzheimer disease .YMALZEN is potentially a repositionned first-in-class clinical stage drug candidate.

Market Analysis:

Alzheimer's disease is a chronic neurodegenerative disorder that alters cognitive functions and memory. The number of patients is estimated to be 5 millions in the US, 7 millions in EU and 36 millions worldwide These numbers are expected to triple by 2050 as a result of an expanding aging population. The economic burden for the society has been estimated to 565 billion euros which represent 1% of world GDP (WHO2010). There is currently no effective treatment that can cure or slow down disease progression. 4 prescribed drugs are known not satisfactory as they only provide modest symptomatic relief with strong side effect. Alzheimer market is estimated between 20 and 40 billions euros/year.

Value proposition:

ORPHIT plans to demonstrate efficacy in a phase IIa clinical trial by 2020. In last 20 years development strategies focused on beta amyloid protein alone and have failed. YMALZEN is potentially first-in-class as it proposes a global response combining neuro-protection and modulation of neuro-inflammation ; ORPHIT proposes a derisked development plan as YMALZEN: 1/ has already achieved a successful phase I 2/ targets CNS as it passes Brain Blood Barrier 3/ is easy and cheap to manufacture which gives affordable chronic treatment costs 4/ is currently being developed in a subcutaneous long action delivery form that will give to patient a comfort of use and will secure treatment compliance

Business Model:

ORPHIT seeks partnership with pharma companies - based on licensing out model - to develop YMALZEN until demonstration of therapeutic efficacy in a phase IIa clinical trial by 2020 latest Following rather conservative milestones can be anticipated: 1/upon confirmation of efficacy in transgenic animal model :2 Meuros by end 2017 2/upon completion of pilot clinical study:5 Meuros by end 2018 3/upon completion of phase IIa clinical study:10 Meuros by end 2020 these revenues will enable ORPHIT to further develop YMALZEN in neurodegenerative diseases with highly unmet medical needs such as Parkinson's disease or Huntington

IP and Regulatory situation:

ORPHIT owns full ownership of the Intellectual Property and know-how related to YMALZEN with an indication patent that covers use of this peptide in neurodegenerative disorders including Alzheimer's disease granted in France (FR2962335B1), EU(EP2593129B1) and USA(US9192654B2) On going development of the long action form of YMALZEN will give us opportunity to file additional patents on the new formulation, the new manufacturing process and the improvement of pharmacokinetic properties of our peptide when subcutaneously administered



COMPANY PROFILE

- **Website:**
www.orphitpharma.com
- **Field:**
- **Contact:**
LARUELLE Stephane
stephane.laruelle@orphitpharma.com
- **Location:**
résidences panoramiques, villa
B 1093 chemin des plateaux
fleuris
06700 saint laurent du var
France
- **Founded in:** //01/2015
- **Employees:** 1
- **Financial information (€):**
 - **Company stage:**
Proof Of Concept
 - **Capital raised to date:**
200 keuros
 - **Monthly burn rate:**
10 keuros
 - **Capital seeking and date:**
1 Meuros by end 2017
- **Investors:**
stephane Laruelle